Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) is a biotechnology company in the clinical stage. It aims to improve the efficacy of current standard-of-care treatments, such as radiation therapy and chemotherapy, to increase the life expectancy of cancer patients.

Key Highlights:

• The company has yet to record revenue from operations, and it does not anticipate generating revenue from product sales shortly.
• The net loss in Q3FY21 jumped to USD 12.20 billion from USD 4.44 billion in Q3FY20, owing to a USD 8.64 billion impairment charge on in-process research and development.
• The company is constantly issuing its common stock and warrants, which dilutes existing shareholders' holdings and diminishes their ownership in the company.
• Stock is currently trading below its crucial short-term as well as long-term 50-day and 200-day SMA support levels, a bearish indicator.
• Stock is currently leaning towards the lower end of the 52-week range of USD 0.22 to USD 1.85.
• DFFN's share price has declined 56.12% and 67.83% in the past six and nine months, respectively.

Technical Price Chart (as of January 28, 2022). Analysis by Kalkine

Conclusion: The company has not reported any revenues to date. Given the unstable fundamentals, lack of clarity in top-line growth, and bleak outlook, we recommend an "Avoid" rating on the stock at the closing price of USD 0.2414, down 0.45%, as of January 28, 2022.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer

References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.

This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414.

The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.

Kalkine Media Limited, an affiliate of Kalkine Limited, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.